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Abstract Compared to classical oncological outcome
measures such as time to progression and survival, the
importance of cognitive functioning in patients with diffuse
inﬁltrative brain tumors has only recently been recognized.
Apart from the relatively low incidence and the invariably
fatal outcome of gliomas, the general assumption that
cognitive assessment is time-consuming and burdensome
contributes to this notion. Our understanding of the effects
of brain surgery on cognition, for instance, is largely based
on studies in surgical patients with refractory epilepsy, with
only a limited number of studies in surgical patients with
gliomas. The impact of other factors affecting cognition in
glioma patients such as direct tumor effects, radiotherapy
and chemotherapy, and medical treatment, including anti-
epileptic drugs and steroids, have been studied more
extensively. The purpose of this paper is to provide an
overview of cognition in patients with diffuse inﬁltrative
gliomas and the impact of resective surgery as well as other
tumor and treatment-related factors.
Keywords Glioma  Cognitive function  Neurosurgery 
Radiotherapy  Epilepsy  Medical treatment
Introduction
Although an increasing number of studies indicate that
primary brain tumors and their treatment are often associ-
ated with cognitive deﬁcits, there is still limited knowledge
about their incidence, nature, severity, and causes. Since
patients with diffuse inﬁltrative gliomas (WHO grade 2–4)
cannot be cured, palliation of symptoms and maintenance
or improvement of physical functioning and health-related
quality of life (HRQOL) are important goals of treatment.
Evaluation of treatment in these patients should thus not
only focus on (progression-free) survival, but should also
aim at functional outcome and at adverse treatment effects
on the normal brain. Functional outcome refers to neuro-
logical, cognitive, professional, and social performance of
an individual, usually abstracted as HRQOL. With regard
to the effects of tumor and treatment on the normal brain,
cognitive functioning is a useful outcome measure for brain
tumor patients, since cognitive deﬁcits, even mild, may
negatively affect HRQOL [1], professional reintegration,
interpersonal relationships, and leisure activities.
Many potential factors contribute to cognitive func-
tioning. In attempting to determine the isolated effect of
resective surgery on cognition, the multifactorial processes
involved should be recognized. These factors include pre-
morbid level of cognitive functioning, distant mechanical
effects on the normal brain by the lesion, epilepsy, medi-
cation, and other oncological treatments.
Cognitive functioning and HRQOL assessment are used
as secondary outcome measures in several clinical trials and
canalsoserveasanearlyindicatorofdiseaseprogressionand
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DOI 10.1007/s11060-012-0811-xhave prognostic signiﬁcance [2, 3], thereby providing addi-
tional arguments in clinical decision making. To illustrate
the clinical decision making process, a typical patient is
described. This case description allows us to describe the
patterns of cognitive functioning related to tumor and/or
treatment within an ecological context, stressing the
importance of conceptualizing patients’ cognitive deﬁcits,
theirfamilies,andtheircaregiversasanintegrated‘‘system’’
withallthehumanisticandethicalaspectsthatentails,rather
than as cognitive deﬁcits in isolation.
A36-yearoldfemalepresentedwithseveralelementary
seizures in the 3 months preceding presentation, char-
acterized by foul smell followed by inattention and
dysphasia. Otherwise she suffered from fatigue for
10 years which was diagnosed as ‘chronic fatigue syn-
drome’. She was married, had one child and worked as
an administrative employee in an international organi-
zation. She had a normal neurological examination and
was right-handed. The ﬁrst MRI showed a T2/FLAIR
hyperintense lesion of 50 ml anterior in the left insula
with no enhancement after gadolinium suggesting a
low-grade glioma (Fig. 1a). She started on carbamaze-
pine200 mgbid.Informationwasprovidedonresective
surgery with its presumed beneﬁcial impact on time to
progression and survival, the acceptable low risk of
permanent neurological deﬁcits when using brain
Fig. 1 Rapid transformation from a WHO grade II oligodendroglioma at the time of surgery into an anaplastic oligodendroglioma at 22 months
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123mapping under local anesthesia, and the unknown risk
of cognitive decline, as well as alternative treatment
options consisting of a biopsy and radiotherapy or che-
motherapy and radiological follow-up with delayed
treatment. She was highly motivated to undergo resec-
tive surgery with language mapping. A baseline
assessment for language and neuropsychological
examination was obtained showing a score on the
Boston naming test in the lower normal range.
Tumor and surgery effects
Apart from seizures, as presented by the patient in our case
description,braintumorpatientsmaypresentwithheadaches,
focal neurologic signs, and cognitive impairment. Cognitive
deﬁcits associated with brain tumors can be induced by
compression of normal brain either directly or indirectly by
reactive edema. Reduction of compression has not only been
shown to improve cognitive function after removal of non-
invasive lesions such as meningiomas [4], associated with
improvement in attentional functioning, or arachnoidal cysts
[5], associated with better dichotic perception and overall
memory performance in patients but even after cranioplasty
[6], where post surgery patients had improved language and
reasoning abilities. Apart from compression, the invasion of
parenchymal glial tumors directly into functional brain
regionsorindirectlybydisconnectionofstructurescanfurther
contribute to cognitive deﬁcits [7–9].
After radiological diagnosis, resective surgery is usually
the ﬁrst of several treatment modalities for patients with
brain tumors. Resective surgery aims to balance functional
outcome (e.g., minimization of neurological deﬁcits) with
oncological outcome (e.g., maximization of tumor
removal) to improve survival. A vast body of literature
exists on the impact of surgery for a variety of brain lesions
on neurological outcome, such as motor strength and lan-
guage. However, due to the limited number of studies
including pre- and postoperative cognitive evaluations, the
true incidence and extent of cognitive dysfunction specif-
ically related to resective brain tumor surgery is unknown.
The patient had a resection in which the brain struc-
tures involved in language determined the boundaries
of resection (Fig. 1b, c). A subtotal resection of 92%
(4 ml residual tumor) was obtained (Fig. 1d). After
surgery in the ﬁrst week a mild dysnomia completely
resolved, and her fatigue was increased for 2 months.
The pathology was oligodendroglioma WHO grade 2.
No adjuvant treatment was advised and she had
radiological follow-up every 6 months.
Cognitiveoutcomeafterresectivesurgeryfortemporallobe
epilepsy and for brain tumors will be discussed, respectively.
Studies in patients with non tumor-related intractable
epilepsy showed cognitive improvement (e.g., memory or
verbal ﬂuency) with adequate seizure control after temporal
resections [10–16]. Less extensive resection of the mesio-
temporal structures seems to correlate with better memory
outcomecomparedwithmoreextensivetemporallobectomy
according to some groups [17–19], whereas others have
reported conﬂicting observations [20–22]. Furthermore,
dominanttemporalloberesectionshavebeencorrelatedwith
verbal memory decline in a subset of patients [23–29],
whereas non-dominant temporal lobe resections were cor-
related with visuospatial memory decline [29–35].
Studiesofextra-temporalresectivesurgeryforintractable
epilepsy also yielded variable cognitive outcomes. After
unilateral removal of frontal cortex cognition was either
unchanged [36, 37], or speciﬁc cognitive domains were
impaired, such as reaction time [38, 39], impulsivity [40],
advance information utilization [41], conditional learning
[42], or search and retrieval strategies [43]. Furthermore,
identiﬁcation of faces and categorization of emotional facial
expression was impaired after either frontal or temporal
cortex resection [44]. Olfactory identiﬁcation was impaired
following unilateral excision of the temporal lobe or the
orbitofrontal cortex on either side [45].
Cognitive outcome has not been systematically assessed
for resective brain surgery in patients with brain tumors,
although several interesting observations have been done in
smaller observational cohort studies.
Firstly, cognitive improvement has been observed in
several studies after brain tumor resection. Long-term
improvement of verbal memory compared to preoperative
assessment has been reported after low-grade glioma
resections in frontal premotor and anterior temporal areas
[46–48], usually after a transient immediate postoperative
worsening. Additionally, regardless the precise tumor
location, patients with low-grade gliomas in the right
hemisphere run a lower risk of developing cognitive deﬁ-
cits after surgery [49]. Cognitive improvement has
also been observed after surgical resection of high-grade
gliomas [50], speciﬁcally in word ﬂuency, verbal memory,
and visuospatial memory. However, one study also sug-
gests that tumor histology might not be that important in
the prediction of cognitive outcome following surgery [49].
Secondly, in some studies stable cognitive performance
was observed after brain tumor resection. For instance,
patients with tumors of the third ventricle demonstrated
cognitive impairment in memory, executive functioning,
and ﬁne manual speed prior to surgery, without worsening
of cognition after surgical removal [51, 52]. Out of several
executive tasks, only letter ﬂuency performance was
impaired in patients after glioma surgery in left frontal
locations compared with right frontal and posterior lesions
[53]. Visuospatial processing in patients after resective
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tions was comparable to that of normal subjects according
to one study [54] and impaired spatial and positional
memory processing was demonstrated in patients with
tumors in the right posterior parietal cortex or in the frontal
cortex according to others [55, 56].
Thirdly, a number of studies have demonstrated cogni-
tive deﬁcits in speciﬁc domains after brain tumor removal.
For instance, some patients demonstrated minor deterio-
ration in attention after resection of parenchymal frontal or
precentral tumors [47, 57] and resection of the right
prefrontal cortex rather than the left was associated with a
selective attentional impairment in Stroop test performance
[58]. After resection of the supplementary motor area,
patients exhibited impaired procedural learning and agra-
phia [59, 60]. Subsets of patients with resections involving
the frontal lobe demonstrated a variety of deﬁcits. For
instance, impaired sequence ordering of novel material was
observed particularly in right-sided lesions, while recog-
nition memory was unaffected [61], and planning and
executive impairment, irrespective of side, site, and size
[62, 63]. Furthermore, severe executive deﬁcits in a reward
learning task were observed in patients after bilateral
fronto-orbital resections for various tumor types [64] and
impaired virtual planning of real life activities after
resections in the left and right prefrontal cortex, which
could not be explained by memory deﬁcits [65, 66].
In the year following surgery she noted more difﬁculty
concentrating, and she was seizure free for 10 months,
after which similar seizures reappeared, for which the
carbamazepine was increased to 300 mg bid. After a
yearshedivorcedfromherhusbandandstartedworking
as volunteer in a nursing home. Follow-up MRIs dem-
onstrated slow increase of residual T2/FLAIR hyperin-
tensity of approximately 4 mm per year. At 21 months
her clinical condition is unchanged, but now there is a
very extensive T2/FLAIR hyperintense inﬁltration and
new multifocal gadolinium enhancement at the genu of
the corpus callosum and left prefrontal area (Fig. 1e).
Several options were considered: (1) radiotherapy and
possibly adjuvant temozolomide at further progression,
(2) new histopathology by either biopsy or limited
resection, in case WHO grade 3 would be conﬁrmed
participation in a trial, in case WHO grade 4 would be
conﬁrmed chemo-irradiation. Because new histopa-
thology would have implications for the radiotherapy
plan, participation in a trial or concurrent temozolo-
mide,anewhistopathologicaldiagnosiswasadvisedby
open biopsy, which would be methionine PET-guided
towards the most anaplastic focus which was located
prefrontally. The pathologist conﬁrmed anaplastic
oligoastrocytomawithoutnecrosis,without1p/19qloss,
and with an extraordinarily high MIB1 labeling index.
The rapid radiological progression in combination with
the high labeling index were the arguments to start
radiotherapy plus concomitant and adjuvant temozolo-
mideatthispoint.Shereceived59.4 GyusingRapidArc
technique. Again she developed more intense fatigue,
lost 10 kg of weight, and developed a grade 4 throm-
bopenia and fever for which she was hospitalized for
2 weeks. MRI at 25 months, after the third cycle of
adjuvant temozolomide, demonstrated a partial radio-
logical response. Despite a combination of nausea,
extreme fatigue, and anxiety for the future, she com-
pleted six cycles of temozolomide. She was unable to
workandunabletocareforhertwochildrenmostofthe
time.
Radiotherapy
Cognitive deﬁcits are the hallmark of late-delayed
encephalopathy [67], which is an irreversible and pro-
gressive complication that may follow radiotherapy by
several months to many years through vascular injury
causing ischemia of surrounding tissue and demyelination,
local radionecrosis, and cerebral atrophy. The severity of
cognitive deﬁcits ranges from mild or moderate to
dementia with progressive mental slowing and deﬁcits in
attention and memory, occurring in at least 12% of patients
treated with radiotherapy [68]. In these cases, MRI shows
diffuse atrophy with ventricular enlargement as well as
severe conﬂuent white-matter abnormalities [69]. There is
a relation between cognitive status and cerebral atrophy
and leukoencephalopathy [70, 71].
While short-term follow-up studies show limited or
transient effects of radiotherapy [8], a number of studies in
long-term survivors of low-grade glioma (i.e., more than
5 years following radiotherapy) concluded that radiother-
apy in these patients poses a signiﬁcant risk of long-term
leukoencephalopathy and cognitive impairment. Surma-
Aho et al. [72] reported low-grade glioma patients with a
follow-up of 7 years to have more memory deﬁcits after
early radiotherapy than controls without radiotherapy.
Moreover, leukoencephalopathy on MRI was more severe
in the group with postoperative irradiation. A study among
low-grade glioma survivors 6 years following diagnosis
and initial treatment showed that the use of radiotherapy
was associated with poor cognitive function on only a few
tests and not restricted to one speciﬁc cognitive domain
[73]. This ﬁnding suggests that cognitive deﬁcits in these
patients should not be attributed to radiotherapy, but rather
to the tumor itself or other treatment factors, including
epilepsy [74]. Serious memory deﬁcits, however, are still to
be expected when fraction doses exceed 2 Gy [73].
A recent follow-up of the Klein et al. [73] study
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progression-free low-grade glioma patients that had irra-
diation showed a progressive deterioration in attentional
functioning 13 years after radiotherapy while all patients
without irradiation remained stable [70].
Again, the patient was seizure free for 10 months
after chemoirradiation. When the seizures reap-
peared, she switched to levetiracetam 500 mg bid.
Then she developed depressive feelings and lack of
initiative for which she visited a psychologist.
Because this was likely related to the levetiracetam,
carbamazepine was reintroduced.
Epilepsy and antiepileptic drug effects
The mechanism and pattern of seizures in brain tumor
patients is determined by tumor type, tumor location and
peritumoral and genetic changes in brain tumor patients
[75]. Apart from tumor and treatment effects, cognitive
function can be impaired by seizures [76]. An increased
epilepsy burden has been found to adversely affect a broad
range of cognitive functions [74] even to a larger extent
than radiation therapy [73]. Decreased processing speed
and attentional and executive deﬁcits are notable sequelae
of seizures and antiepileptic drugs (AEDs) in patients with
brain tumors [73, 74, 77]. However, the literature is
inconsistent on this point. Others did not detect any
apparent effect of seizures on cognition across multiple
cognitive domains assessed in a postsurgical sample [4].
Cognitive side-effects of AEDs can add to cognitive
decline due to tumor effects, previous surgery, or radio-
therapy, and therefore appropriate choice and dose of AED
is crucial. The classical AEDs (phenytoin, carbamazepine,
and valproic acid) are known to decrease cognitive func-
tioning [78, 79]. Importantly, these drugs may also have
pharmacological interactions with chemotherapy [80, 81]
and thus potentially affect survival. These drugs may result
in impaired attention and cognitive slowing, which can
subsequently have effects on memory by reducing the
efﬁciency of encoding and retrieval [79]. The importance
of the classical AEDs as a risk factor for cognitive deﬁcits
has been reported in a study on stable disease, long-term
low-grade glioma survivors [74] where reduced informa-
tion processing speed, psychomotor function, working
memory capacity, and executive functioning, were signif-
icantly related to the use of AEDs. As patients in this study
who took AEDs had cognitive impairment even in the
absence of seizures, the use of AEDs primarily affects
cognitive function. Moreover, AED use in low-grade
glioma patients may be associated with highly elevated
levels of fatigue [82], which in itself is also associated with
poorer cognitive outcome. Several new generation AEDs,
like oxcarbazepine [83] and levetiracetam as add-on ther-
apy [84], appear to have fewer adverse cognitive effects
than the classical agents. Of the newer agents, topiramate is
associated with the greatest risk of cognitive impairment,
although this risk is decreased with slow titration and low
target doses [85, 86]. It appears to be safe to switch patients
from phenytoin to levetiracetam monotherapy following
craniotomy for supratentorial glioma [87].
Follow-up MRIs of the patient every 3 months
showed a stable response with no gadolinium
enhancement and a T2/FLAIR hyperintense region
that is progressive at 6 mm/year up to 44 months
after initial surgery and 20 months after chemoirra-
diation. During this time she is still unable to work,
and partly able to take care of her children due to
concentration problems, fatigue, and depression.
A considerable number of brain tumor patients have
feelings of anxiety, depression, and future uncertainty as
psychological reactions to the disease [88–90]. These mood
disturbances may lead to deﬁcits in attention, vigilance, and
motivation that subsequently affect several cognitive
domains [91]. Loss of self conﬁdence, unemployment, and
dependency on caregivers may also negatively affect these
patients’ cognitive status. Mood changes are more common
in brain tumor patients than in patients with other neuro-
logical diseases [92] and might be related to tumor location
[93]. Unilateral surgical removal of prefrontal cortex,
including the fronto-orbital or anterior cingulate cortex, has
resulted in emotional dysregulation with impaired voice and
face expression identiﬁcation in patients with various brain
lesions including brain tumors [94]. Furthermore, deﬁcits in
recognizingemotional facialexpression were observed after
surgical removal of brain tumors that involved both hetero-
modal and limbic/paralimbic cortices [95]. Concordantly,
impairment of arousal and emotional valence was demon-
strated after resective surgery in various brain regions, but
particularly in the right temporoparietal region [96]. This
emotional impairment can have an impact on social and
professional performance. Negative mood changes were
observed after brain tumor resection involving heteromodal
cortices located either prefrontal or temporoparietal,
whereas positive mood changes were observed after lateral
frontal resections [97]. Mood states did not correlate with
laterality of the resection, tumor grading or lesion size.
At 44 months after initial surgery and 21 months
after chemoirradiation, she experienced headache, a
severe decline in cognitive functions, lethargia, and
gait instability without seizures. At neurological
examination she demonstrated bradyphrenia, disori-
entation, and a right-sided hemiparesis. She was
admitted and a new MRI showed clear and sudden
J Neurooncol (2012) 108:309–318 313
123progression with extensive T2/FLAIR inﬁltration,
and new gadolinium enhancement at the corpus of the
corpus callosum and in the left internal capsula
(Fig. 1). Because of her poor clinical condition and
the extent of radiological progression, no further
treatment options were considered and she received
dexamethasone. She was discharged to a hospice and
died at 46 months after initial surgical treatment.
Corticosteroids
The potentially neurotoxic effects of corticosteroids are
often misdiagnosed and underestimated [98] and cortico-
steroids may induce behavioral, psychic, and cognitive
disturbances, due to functional and, over time, structural
alterations in speciﬁc brain target areas. Corticosteroids
may cause mood disturbances, psychosis, and cognitive
deﬁcits particularly in declarative memory performance.
Steroid dementia is a reversible cause of cognitive deﬁcits
even in the absence of psychosis. Recent data suggest that
transiently impaired attention, concentration, and memory
are due to neurotoxic effects on both the hippocampal and
the prefrontal areas [99]. Both short-term and long-term
use of steroids has been associated with hippocampal-
dependent explicit memory deﬁcits [100]. More likely,
however, corticosteroids may improve cognitive deﬁcits
because of resolution of edema [101].
Relevance of neuropsychological testing
Comprehensive assessment of neurocognitive function is
evidently different from the use of standard HRQOL
measures, which is considered to be relatively easy and not
time-consuming. However, while cognitive deterioration
can be predictive of radiologic disease progression in
patients with tumor recurrence [102], measures of HRQOL
and activities of daily living are only weakly correlated to
cognitive decline or to time to tumor progression, sug-
gesting that HRQOL measures may not be sensitive enough
to detect a change in patient function [102]. It should be
noted, on the other hand, that HRQOL is an important
outcome measure within the context of patient care [102].
Self-reported HRQOL measures or other methods of
informal assessment of cognitive function depend on the
patient’s report of their cognitive symptoms. Self-reports of
decreased cognitive functioning au lieu of formal neuro-
psychological testing not only usually point at feelings of
anxiety, depression, or fatigue rather than cognitive deﬁcits
[103, 104], and use of self-reports is even more problem-
atic in brain tumor patients whose judgment may be
severely impaired by the tumor [73].
Surgical treatment considerations
Historically, when a low-grade glioma was diagnosed in a
young, healthy adult, a commonly accepted strategy was a
‘‘wait and see’’ policy because of the presumed indolent
nature and variable behavior of these tumors. However,
retrospective studies of the kinetics of glioma growth,
showed linear growth before anaplastic transformation
[105]. The majority of low-grade gliomas are now known
to progress to malignant gliomas with time. A better
understanding of the natural history of low-grade gliomas
has led to an interest in early treatment. The decision as to
whether a patient with low-grade glioma should receive
resection, radiotherapy, or chemotherapy is based on a
number of factors including age, performance status,
location of tumor, and patient preference. Since low-grade
gliomas are such a heterogeneous group of tumors with
variable natural histories, the risks and beneﬁts of each of
the three therapies must be carefully balanced with the data
available from limited prospective studies. Since patients
with low-grade gliomas can survive in a clinically stable
state for several years after diagnosis, the long-term effects
of the disease and its treatment on cognitive functioning of
these long-term survivors are especially salient. Although
not Class I evidence, numerous studies strongly suggest
that more extensive surgical tumor resection is associated
with longer life expectancy for both low- and high-grade
gliomas [106]. At the same time, the rapid development of
operative techniques and technologies, including brain
mapping techniques aimed at preserving eloquent brain
functions [107], facilitates the attainment of maximal or
radiologically complete tumor resection while minimizing
morbidity. Recently, supratotal resection extending beyond
the radiological boundaries of the tumor, has been postu-
lated to improve both survival and perseveration of func-
tion [108].
Conclusions and assessment recommendations
for neurocognitive testing
Cognitive functioning of brain tumor patients is an increas-
ingly important outcome measure, because cognitive
impairments can have a large impact on self-care, social and
professional functioning, and consequently on HRQOL.
Many factorscontribute tocognitive outcome,suchasdirect
and indirect tumor effects, seizures, medication, and onco-
logical treatment. Review of the literature indicates that
neurocognitive outcome in patients with primary brain
tumorswasassessedsystematicallyinonlyalimitednumber
of studies, and most involved a relatively small number of
patients. Due to the absence of pretreatment neurocognitive
assessments and treatment randomization the ability to
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including surgery, was limited in the retrospective studies.
However, studies among long-term low-grade glioma sur-
vivors indicated greater impairments in virtually all neuro-
cognitive domains in patients who had radiotherapy
compared to those who had not. Although the role of radio-
therapy—for a long time thought to be the main cause of
cognitive deﬁcits in patients with brain tumors—has been
studiedextensively,theadverseeffectsoncognitivefunction
of other tumor and treatment-related factors remain elusive.
As far as resective surgery is concerned, both cognitive
improvement and decline have been observed depending on
pathology, lesion size, localization and laterality. Neuro-
cognitive deﬁcits, if present, are transient in most cases,
except for low-grade glioma patients with tumors in the left
hemisphere. AEDs may result in impairments of attention
and neurocognitive slowing, which can subsequently have
effects on memory by reducing the efﬁciency of encoding
and retrieval. Cognitive outcome after resective surgery for
brain tumors has not been systematically determined. Like-
wise, intrasurgical cognitive mapping to improve cognitive
outcome also has not been systematically applied in these
patients. Concerted action into studying the costs and
beneﬁts of presurgical, intrasurgical, and postsurgical cog-
nitiveassessmentsrelatedtooutcomeofthesepatientsisthus
warranted.
Since a combination of cortical and subcortical lesions,
epilepsy, surgery, radiotherapy, AEDs, corticosteroids, and
psychological distress is likely to contribute to neurocog-
nitive dysfunctioning in an individually unpredictable way,
it would be most pragmatic to choose a core testing battery
that gauges a broad range of neurocognitive functions.
Additionally, the neuropsychological measures have to
meet the following criteria: (i) assess several domains
found to be most sensitive to tumor and treatment effects;
(ii) have standardized materials and administration proce-
dures; (iii) have published normative data; (iv) have
moderate to high test–retest reliability; (v) have alternate
forms or are relatively insensitive to practice effects, and
are therefore suitable to monitor changes in neurocognitive
function over time; (vi) include tests that have been
translated into several languages (i.e., Dutch, English,
French, German, Hebrew, Italian, Turkish) [109] or require
translation primarily of test directions; and (vii) total
administration time is 30–40 min. The neurocognitive
domains deemed essential to be evaluated include atten-
tion, executive functions, verbal memory, and motor speed.
The test battery that meets most of the afore-mentioned
criteria has successfully been used and is still being used in
a number of EORTC, NCCTG, NCI-C, RTOG, MRC, and
HUB multisite clinical trials and it has been shown that
neurocognitive functioning has independent prognostic
signiﬁcance in patients with low-grade glioma [110].
Moreover, neurocognitive deterioration indicates tumor
progression before signs of disease recurrence are evident
on CT or MRI [3, 102, 111]. This battery assesses: memory,
Hopkins verbal learning test [112], which is a list of 12
words in 3 semantic categories that measures immediate
recall across 3 trials, recognition of the words from dis-
tractors, and delayed recall; verbal ﬂuency, controlled oral
word association [113], which requires the production of
words beginning over a speciﬁc letter for three 1-min trials;
visual-motor scanning speed, trail making test part A [114],
which requires the subject to connect dots in numerical
order as rapidly as possible; executive function, trail mak-
ing test part B [114], which requires the subject to connect
dots with alternating numbers and letters as rapidly as
possible.
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